Hikal Ltd, the outsourcing partner for pharmaceuticals, biotech, agrochemicals and speciality chemicals industries announced that the company's multipurpose facility to manufacture active pharmaceutical ingredients (APIs) will be operational by June 2012.
The company also informed that it will supply a wide range of APIs from its Bangalore facility to its customers in markets like the US, Europe, South East Asia, Latin America, Canada and Japan. This was the company's third site approval as a result of the US FDA audit at the facility located at Jigani near Bangalore.
Hikal is building a new multipurpose API facility at this site would meet additional demands from its US, European and Japanese customers. The plant will be operational by June 2012 and can accommodate 32 reactors with capacities ranging from 6 m3 to 10 m3.
This will result in a total reactor volume of approximately 300m3.
The company has appointed Peter Nightingale as the president of its 100 per cent contract research subsidiary, Acoris Research Ltd, Pune, India. Nightingale is a PhD in chemistry from the University of Manchester, United Kingdom and is a process development chemist with over three decades of experience in the pharmaceutical, agrochemical and fine chemical sectors.
"We are pleased to announce the appointment of Dr Nightingale as the president of Acoris Research Ltd. Dr. Nightingale’s extensive experience in the adaptation of new technologies in chemistry and as a veteran process development chemist will be a great asset to Acoris Research," said Jai Hiremath, vice chairman and managing director, Hikal.